Stockscreener 앱 받기
2.06
6.74%
0.13
전일 마감가:
$1.93
열려 있는:
$1.92
하루 거래량:
337.31K
Relative Volume:
1.04
시가총액:
$240.71M
수익:
-
순이익/손실:
$-13.73M
주가수익비율:
-15.85
EPS:
-0.13
순현금흐름:
$-3.92M
1주 성능:
+4.57%
1개월 성능:
+27.16%
6개월 성능:
+151.25%
1년 성능:
+64.80%
1일 변동 폭
$1.906
$2.07
1주일 범위
$1.7256
$2.07
52주 변동 폭
$0.6295
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
2.06 | 220.84M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Trendlines Suggest Tiziana Life Sciences Ltd May Bottom Out SoonJuly 2025 Gainers & High Accuracy Trade Alerts - thegnnews.com
Price Reversal in Tiziana Life Sciences Ltd Traders Watch CloselyEarnings Performance Report & AI Driven Stock Reports - 선데이타임즈
We Think Tiziana Life Sciences (NASDAQ:TLSA) Can Easily Afford To Drive Business Growth - 富途牛牛
Is Tiziana Life Sciences Ltd stock bottoming outMarket Movement Recap & Risk Controlled Stock Alerts - Newser
Using economic indicators to assess Tiziana Life Sciences Ltd potentialJuly 2025 Institutional & Expert Approved Trade Ideas - Newser
What institutional flow reveals about Tiziana Life Sciences Ltd2025 Pullback Review & Free Growth Oriented Trading Recommendations - Newser
Tiziana Life Sciences Ltd Inches Toward Key Resistance — Will It BreakWeekly Market Outlook & Weekly Sector Rotation Insights - 선데이타임즈
Multi factor analysis applied to Tiziana Life Sciences LtdJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Analyzing Tiziana Life Sciences Ltd with multi timeframe chartsPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Can Tiziana Life Sciences Ltd hit a new high this monthMarket Performance Summary & Real-Time Stock Entry Alerts - Newser
Why Tiziana Life Sciences Ltd stock attracts strong analyst attentionMarket Weekly Review & Reliable Volume Spike Trade Alerts - Newser
Is Tiziana Life Sciences Ltd in a bullish channel2025 Price Targets & Long-Term Growth Plans - thegnnews.com
Can Traders Expect Breakout From Tiziana Life Sciences Ltd This WeekQuarterly Profit Review & Reliable Entry Point Alerts - metal.it
Smart tools for monitoring Tiziana Life Sciences Ltd’s price actionJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Should you hold or exit Tiziana Life Sciences Ltd nowJuly 2025 Breakouts & Weekly Watchlist of Top Performers - Newser
Tiziana Life Sciences Ltd stock momentum explainedWeekly Investment Report & Verified Stock Trade Ideas - Newser
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI - Proactive financial news
Screener Results Flag Tiziana Life Sciences Ltd as Oversold2025 Risk Factors & Weekly Breakout Opportunity Watchlist - kangso.co.kr
Will Tiziana Life Sciences Ltd stock benefit from interest rate changesPortfolio Value Summary & High Yield Stock Recommendations - Newser
Applying sector rotation models to Tiziana Life Sciences LtdM&A Rumor & AI Driven Price Forecasts - Newser
Tiziana Life Sciences shares rise 2% premarket after dosing first patient in Phase 2a trial for MSA. - AInvest
Tiziana Life Sciences doses first patient in Phase 2a trial of Foralumab for rare disease - Proactive financial news
RSI Suggests Rebound May Be Near in Tiziana Life Sciences LtdWatch List & Precise Swing Trade Entry Alerts - newsimpact.co.kr
Tiziana Life Sciences doses first patient in Phase 2a MSA trial - Proactive financial news
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy - The Manila Times
Novel Intranasal Treatment Begins Trial for Incurable Brain Disorder Affecting 50,000 Americans - Stock Titan
What makes Tiziana Life Sciences Ltd stock price move sharplyJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Top chart patterns to watch in Tiziana Life Sciences LtdBuy/Sell Zone Confirmation Technical Analysis - Newser
What moving averages say about Tiziana Life Sciences Ltd [Trade Analysis Report]Free Real-Time Buy Signal Notifications - Newser
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Decreases and Increases - investchronicle.com
Has Tiziana Life Sciences Ltd formed a bullish divergenceEquity Market Return Forecast Model Update - Newser
Tiziana Life’s Phase IIa multiple system atrophy study gets FDA approval - Yahoo Finance
How to interpret RSI for Tiziana Life Sciences Ltd stockPredictable Return Plan with Entry Guidance - Newser
What high frequency data says about ENDRA Life Sciences Inc.Entry and Exit Strategy for Swing Traders - Newser
What analysts say about Tiziana Life Sciences Ltd stock outlookDaily Technical Forecast for Quick Gains - Newser
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy - Informazione.it
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive financial news
Market movers: Micron, Barrick, Tiziana Life Sciences, American Resources... - Proactive financial news
What moving averages say about Tiziana Life Sciences LtdSteady Return Plan Based on Data Analysis - Newser
Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA - Proactive financial news
Tiziana to begin testing foralumab in multiple system atrophy - Seeking Alpha
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):